Éva Malpass
GEST 2023: AI enables “more effective” research and practice development
Discussing the role of artificial intelligence (AI) in improving outcomes within research and practice development, Hamid Mojibian (Yale School of Medicine, New Haven, USA)...
Predictions made on the future of embolization at GEST 2023
Speaking in the Vanguard session on the first day of the 2023 Global Embolization Oncology Symposium (GEST, 18–21 May, New York City, USA) yesterday,...
IO of the past, present and future: presentation predicts what is...
Setting the audiences sights on the horizon at the 2023 Global Embolization Oncology Symposium (GEST, 18–21 May, New York City, USA) yesterday, Daniel Sze...
First US patient is enrolled in MedAlliance sirolimus DEB study
The first US patient has been enrolled in the SELUTION4SFA sirolimus drug-eluting balloon (DEB) study by Arthur Lee (Cardiac & Vascular Institute, Gainesville, USA)....
BlackSwan is given FDA premarket approval for new treatment of peripheral...
BlackSwan Vascular, a privately held company that is developing innovative therapies in endovascular embolization, is has announced it has received US Food and Drug...
Clinical trial continuation announced for robot-assisted treatment for lung metastases
Quantum Surgical announces the ongoing clinical trial for the treatment of lung metastases assisted by the Epione robot.
The study is coordinated by Thierry...
Humacyte publish six-year outcomes in study of HAV for peripheral arterial...
Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced...
Cook Medical appoints John A Kaufman as chief medical officer
Cook Medical announces John A Kaufman (Cook Medical, Bloomington, USA) will be joining as its chief medical officer, effective July 2023. With Kaufman’s expertise...
Boston Scientific announces partial acquisition offer for majority stake of Acotec...
Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares...
Non-surgical treatment found to provide long-term relief for carpal tunnel syndrome
A minimally invasive treatment for carpal tunnel syndrome provides complete and long-term relief to patients without the use of corticosteroids, according to research presented...
Otsuka Medical Devices and ReCor Medical submit pre-market approval of Paradise...
Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the pre-market approval (PMA) application to the US Food and...
